Nano-X Imaging (NNOX) investor relations material

Company overview and business model

• Focuses on making diagnostic medicine more accessible and affordable globally through proprietary medical imaging technology and solutions, including the Nanox System (Nanox.ARC hardware and Nanox.CLOUD software), AI imaging solutions, healthcare IT, and teleradiology services.

• Nanox System leverages a novel digital MEMS X-ray source, aiming to disrupt legacy X-ray and CT imaging by reducing costs and complexity.

• Business model includes modular and end-to-end imaging solutions, with a hybrid approach in the U.S. (usage-based MSaaS and CapEx) and CapEx-focused sales in the EU.

• Offers AI-based population health solutions, teleradiology, and a decentralized marketplace for remote imaging interpretation.

Financial performance and metrics

• As of December 31, 2025, 69,590,228 ordinary shares were issued and outstanding.

• The company has never declared or paid cash dividends on its ordinary shares.

• Financial statements and internal control effectiveness are audited by Kesselman & Kesselman, a member of PwC.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for research funding, general corporate purposes, commercial efforts, acquisitions, working capital, and capital expenditures.

• Management has broad discretion over allocation of proceeds.